BCM
LUMO

BlueCrest Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

BlueCrest Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,419
Closed -$93K – 1890
2018
Q1 		$93K Buy
+1,419
New +$101K ﹤0.01% 1375

Other funds holding LUMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlueCrest Capital Management's LUMO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 1,419 shares — an estimated $93K sold.

BlueCrest Capital Management first reported a position in LUMO in Q1 2018 and held it in 1 quarter. The position peaked at $93K in Q1 2018. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,419 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $93K.
  • BlueCrest Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $93K in Q1 2018.
  • 106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.